Orion Corporation Acquires Own Shares as Part of Buyback Program

Orion Corporation, a globally operating Nordic pharmaceutical company, has announced the acquisition of its own shares during week 38 of 2026. This acquisition forms part of a share buyback program that the company announced on August 27, 2026. The buyback program, which runs from September 1, 2026, until no later than December 31, 2026, is being executed in compliance with Regulation No. 596/2014 of the European Parliament and Council (MAR) Article 5 and the Commission Delegated Regulation (EU) 2016/1052.

As of the latest update on September 18, 2026, at 19:00 EEST, Orion Corporation has acquired a total of 616,646 Class B shares. These acquisitions are part of the company's ongoing efforts to manage its capital structure and return value to shareholders. The company's treasury shares now total 616,646, all of which are Class B shares.

Orion Corporation, headquartered in Finland, is a builder of well-being, with a focus on developing, manufacturing, and marketing human and veterinary pharmaceuticals, as well as active pharmaceutical ingredients. The company's research and development (R&D) efforts are primarily concentrated in core therapy areas such as oncology and pain. In 2025, the company reported net sales of EUR 1,890 million, reflecting its significant market presence and financial strength. With a global workforce of approximately 4,000 professionals, Orion Corporation is dedicated to advancing healthcare through continuous innovation and expertise.